Business Update

Rohto announces exclusive rights agreement with Dynamis Therapeutics on Supplamine

Published in Obesity and Diabetes Week, June 26th, 2006

Rohto Pharmaceutical Co., Ltd. announced its agreement with Dynamis Therapeutics Inc. (Dynamis), a venture company engaged in the R&D of drugs for the treatment of diabetic complications, to be granted the exclusive use rights of Supplamine, patented by Dynamis, and its appertaining technology.

In conjunction with the signing of this contract, Rohto will take a capital interest in Dynamis in order to put the partnership on a firmer footing.

Rohto has been conducting research into skin aging as one of its key skincare product development themes. Consistent efforts had been directed toward the identification of agents effective in preventing skin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2006-06-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry